Biologics Safety: Infection Risk, Screening, and Vaccination Guidance for Autoimmune Patients

When you're managing an autoimmune condition like rheumatoid arthritis, psoriasis, or Crohn’s disease, biologics can be life-changing. These targeted drugs - monoclonal antibodies and fusion proteins - stop the immune system from attacking your own body. But there’s a trade-off: they also make you more vulnerable to infections. That’s not just a small risk. It’s a real, measurable threat that can land you in the hospital. The good news? You don’t have to live in fear. With the right screening, timing, and vaccination plan, you can take biologics safely - and stay healthy for years.

Why Biologics Increase Infection Risk

Biologics work by blocking specific parts of your immune system. TNF inhibitors like adalimumab and infliximab are the most common, making up about 68% of all biologic prescriptions. They’re powerful, but they also remove a key defense against bacteria, viruses, and fungi. Studies show patients on these drugs have a 2.1 times higher risk of serious infections that require hospitalization compared to those on older medications like methotrexate. The risk isn’t the same for everyone. Age, other health conditions, and even the specific drug matter.

If you’re over 50, your risk climbs 37% with each passing decade. If you’re taking steroids like prednisone at more than 10 mg a day, your infection risk jumps by more than double. Conditions like diabetes, chronic kidney disease, or COPD also raise the danger. One study found that patients with COPD had more than double the risk of serious lung infections on biologics. It’s not just about the drug - it’s about your whole health picture.

Which Biologics Carry the Highest Risk?

Not all biologics are created equal when it comes to infection risk. TNF inhibitors are the most studied - and they carry the highest risk. Compared to non-TNF biologics, they increase serious infection rates by 1.6 to 1.9 times. But even within this group, there are differences. For example, infliximab at standard doses shows a 22% higher infection rate than adalimumab. Meanwhile, certolizumab pegol, which lacks a key immune component called the Fc region, has 18% fewer respiratory infections than other TNF drugs.

Newer agents like ustekinumab (an IL-12/23 inhibitor) and secukinumab (an IL-17 inhibitor) are generally safer. Ustekinumab, for instance, shows no significant increase in serious infections compared to non-biologic treatments. But it’s not perfect: IL-17 inhibitors raise the risk of candidiasis - fungal infections like thrush or yeast infections - by 1.4 times. JAK inhibitors like tofacitinib, though not technically biologics, are often used alongside them and carry their own risk: a 1.33 times higher chance of shingles.

Here’s the bottom line: If you’ve had hepatitis B before, avoid TNF inhibitors. Reactivation happens in nearly 28% of untreated cases. Ustekinumab, on the other hand, has a reactivation risk under 2%. If you’re prone to fungal infections, your doctor might lean toward a TNF blocker over an IL-17 drug. The choice isn’t one-size-fits-all - it’s tailored to your history.

Screening Before You Start: What You Must Get Tested For

Before your first biologic dose, you need three critical tests - and they must be done at least four weeks before starting treatment. Skipping any one of them puts you at serious risk.

• HBV Screening: You need all three markers: HBsAg (hepatitis B surface antigen), HBsAb (antibody), and HBcAb (core antibody). If HBcAb is positive - even if you don’t have active hepatitis - you have a hidden infection. About 8.7% of these patients will reactivate hepatitis B if they start a TNF inhibitor without antiviral protection. The CDC says this is non-negotiable.
• Tuberculosis: The standard is an interferon-gamma release assay (IGRA), like the Quantiferon test. It’s 98% specific. But here’s the debate: in low-risk areas, some experts argue this test overdiagnoses latent TB. Still, guidelines still recommend it. If you test positive, you’ll need nine months of preventive antibiotics before starting your biologic.
• VZV Serology: Chickenpox and shingles are common in adults. If you’ve never had chickenpox or the vaccine, you’re at high risk for shingles after starting biologics. A simple blood test checks your VZV IgG level. If it’s below 140 mIU/mL, you need the Shingrix vaccine - and it must be given at least four weeks before your first dose.

One patient on HealthUnlocked shared: “My GI doctor started me on Stelara without checking my vaccines. I got shingles four months later.” That’s preventable. Yet, surveys show 41% of patients miss HBV core antibody testing, and 37% never get VZV checked. These aren’t rare oversights - they’re systemic failures.

Vaccination: Timing, Type, and What Works

Vaccines are your first line of defense. But not all vaccines are safe - and timing is everything.

Live vaccines - like MMR (measles, mumps, rubella) and varicella - contain weakened viruses. Your immune system can’t handle them once you’re on biologics. You must get these at least four weeks before starting treatment. If you’ve already started, you can’t get them at all.

Inactivated vaccines - like flu shots, pneumococcal (Prevnar 20, Pneumovax 23), and hepatitis B - are safe. But they need time to work. Get them at least two weeks before your first biologic dose. And don’t assume you’re protected just because you got the shot. For hepatitis B, you need a blood test to confirm your antibody level is above 10 mIU/mL. For VZV, it’s 140 mIU/mL. If you’re not at that level, you need a booster.

Flu shots? Get them every year. Pneumococcal vaccines? Two doses, 12 months apart. Shingrix? Two doses, 2 to 6 months apart - if you’re eligible. A 2023 study found patients who got full pre-biologic vaccination and education had a 78% lower chance of serious infection than those who didn’t. That’s not just a stat - that’s your future.

What Happens After You Start?

The work doesn’t stop after your first injection. You need ongoing vigilance. Upper and lower respiratory infections make up nearly 44% of all serious infections in biologic users. That means pay attention to coughs, fevers, and shortness of breath. Don’t wait. Call your doctor at the first sign.

Also, avoid high-risk environments. Crowded places during flu season? Skip them. Gardening? Wear gloves - soil can carry fungi. Travel? Check CDC alerts. Your doctor should give you a list of symptoms to watch for: fever over 100.4°F, night sweats, unexplained weight loss, or skin sores that won’t heal. These aren’t “wait and see” signs - they’re red flags.

And here’s something few patients know: your biologic records must be kept for 10 years after treatment ends. The FDA requires this. Yet, 23.7% of clinics fail to comply. If you switch doctors or move, make sure your records follow you. You might need them years later.

Real-World Gaps and How to Protect Yourself

The science is clear. The guidelines are solid. But in practice, things fall apart. A 2023 survey of over 2,100 patients found that 63% reported at least one screening or vaccination gap. The most common? Missing HBV core antibody testing. Then VZV. Then pneumococcal vaccine timing.

One patient from Mayo Clinic shared: “They caught my latent TB with the Quantiferon test. I got treated for nine months. Then I started Humira. I’ve had zero infections in three years.” That’s what proper care looks like.

Here’s your action plan:

1. Request the full HBV panel (HBsAg, HBsAb, HBcAb) - don’t accept just one test.
2. Ask for your VZV IgG level - if it’s below 140 mIU/mL, get Shingrix.
3. Get all inactivated vaccines (flu, pneumococcal, hepatitis B) at least two weeks before your first dose.
4. Never get live vaccines after starting biologics.
5. Keep a personal health log: write down every test, vaccine, and date.
6. Ask your doctor for the CDC’s 12-point infection prevention checklist.

If your provider pushes back - “We don’t do that here” - find someone who does. Your safety isn’t optional. It’s essential.

The Future: AI, New Rules, and What’s Coming

The field is moving fast. In 2025, the FDA will require real-world data proving infection risk is lowered before approving new biologic uses. New tools like the Cerner Biologics Safety Algorithm use 87 clinical variables to predict your personal risk - with 87% accuracy. By 2030, over 90% of clinics are expected to follow full safety protocols, thanks to new Medicare payment models that reward safe care.

But until then, you’re your own best advocate. Don’t wait for your doctor to bring it up. Ask. Demand. Document. The data is clear: with the right steps, you can take a biologic and live a full, active life - without ending up in the hospital from an infection that could have been prevented.